NextPharma sells Bioserv but is on the look of for US acquisitions
NextPharma has sold its US contract manufacturing business Bioserv to private equity group Kesa Partners.
Archives for December 4, 2012
Icon guidance suggests margin improvement in 2013
Guidance issued by Icon is at the lower end of consensus estimates but it still suggests that the CROs margins are set to improve.
Guidance on PET sounds starting siren on 3-year NDA race
Positron emission tomography (PET) drug manufacturers have three years to gain NDA or ANDA approval or they must remove their products from the market according to the US FDA.
GVK Biosciences cleared to perform isotope labelling for tox studies
India's national Atomic Energy Regulation Board (AERB) has approved GVK Biosciences to perform certain isotope-labeling research in its facility, according to the Hyderabad-based contract research organization (CRO).
Recipharm adds analytical capacity at Swedish plant
Swedish CMO Recipharm has added capacity for analytical services and stability studies at its laboratory in Solna, Sweden
EMA says mandatory supply chain risk assessments could prevent shortages
The EMA suggests that asking drugmakers to conduct risk assessments of manufacturing processes and supply chains could help prevent shortages.